ADMA BIOLOGICS, INC. (ADMA)
$8.94+$0.04 (+0.45%) Latest session
Kaitlin M. Kestenberg-Messina - OfficerADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 2 | 221,493 | |
| Tax withholding / forfeiture | 1 | 3,177 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
39 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Kaitlin M. Kestenberg-Messina - Officer | Tax withholding / forfeiture | Common Stock | 3,027 | $17.31 | $52K | |
| Brad L. Tade - Officer | Tax withholding / forfeiture | Common Stock | 7,123 | $17.31 | $123K | |
| Adam S. Grossman - Officer | Option exercise | Common Stock | 15,000 | $5.40 | $81K | |
| Adam S. Grossman - Officer | Open-market sale | Common Stock | 15,000 | $18.66 | $280K | |
| Adam S. Grossman - Officer | Open-market sale | Common Stock | 6,000 | $18.66 | $112K | |
| Adam S. Grossman - Officer | Option exercise | Stock Option (right to buy) | 15,000 | $0.00 | - | |
| Steve Elms | Open-market sale | Common Stock | 92,941 | $21.69 | $2.02M | |
| Steve Elms | Option exercise | Common Stock | 9,000 | $5.96 | $54K | |
| Steve Elms | Option exercise | Common Stock | 10,000 | $5.00 | $50K | |
| Steve Elms | Option exercise | Common Stock | 53,837 | $3.66 | $197K | |
| Steve Elms | Option exercise | Common Stock | 17,500 | $4.91 | $86K | |
| Steve Elms | Option exercise | Common Stock | 30,000 | $3.89 | $117K | |
| Steve Elms | Option exercise | Common Stock | 15,000 | $2.92 | $44K | |
| Steve Elms | Option exercise | Common Stock | 55,000 | $2.35 | $129K | |
| Steve Elms | Option exercise | Common Stock | 53,172 | $1.67 | $89K | |
| Steve Elms | Option exercise | Common Stock | 51,630 | $3.35 | $173K | |
| Steve Elms | Option exercise | Common Stock | 37,541 | $5.40 | $203K | |
| Steve Elms | Open-market sale | Common Stock | 137,931 | $20.82 | $2.87M | |
| Steve Elms | Open-market sale | Common Stock | 194,749 | $20.24 | $3.94M | |
| Steve Elms | Option exercise | Stock Option (Right to Buy) | 9,000 | $0.00 | - | |
| Steve Elms | Option exercise | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Steve Elms | Option exercise | Stock Option (Right to Buy) | 53,837 | $0.00 | - | |
| Steve Elms | Option exercise | Stock Option (Right to Buy) | 17,500 | $0.00 | - | |
| Steve Elms | Option exercise | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Steve Elms | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Steve Elms | Option exercise | Stock Option (Right to Buy) | 55,000 | $0.00 | - | |
| Steve Elms | Option exercise | Stock Option (Right to Buy) | 53,172 | $0.00 | - | |
| Steve Elms | Option exercise | Stock Option (Right to Buy) | 51,630 | $0.00 | - | |
| Steve Elms | Option exercise | Stock Option (Right to Buy) | 37,541 | $0.00 | - | |
| Steve Elms | Option exercise | Common Stock | 9,000 | $10.80 | $97K | |
| Steve Elms | Option exercise | Stock Option (Right to Buy) | 9,000 | $0.00 | - | |
| Adam S. Grossman - Officer | Open-market sale | Common Stock | 48,967 | $21.10 | $1.03M | |
| Brad L. Tade - Officer | Open-market sale | Common Stock | 15,000 | $21.15 | $317K | |
| Adam S. Grossman - Officer | Tax withholding / forfeiture | Common Stock | 21,752 | $19.99 | $435K | |
| Kaitlin M. Kestenberg-Messina - Officer | Tax withholding / forfeiture | Common Stock | 2,647 | $19.99 | $53K |
This is as far as the anonymous view goes. Create a free account for all 39 ADMA filings on record.
ADMA BIOLOGICS, INC. (ADMA) had 2 insider filings in the last 90 days, with the most recent on 2026-07-29. The full record for ADMA runs to 39 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ADMA were filed in the last 90 days. 5 purchases are on record for this company.
No insider sales of ADMA were filed in the last 90 days. 22 sales are on record for this company.
This page tracks ADMA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ADMA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
